PCOS is now PMOS. Here is what changed, and why it matters for how you treat it.

Polycystic ovary syndrome was named in 1935, by two American gynecologists who described seven women with cystic-looking ovaries on surgery (Stein and Leventhal, AJOG, 1935). The name stuck for ninety years. It was wrong almost immediately. Most people with the condition do not have cystic ovaries on ultrasound. Many people with cystic-looking ovaries do not have the condition. The cysts are not cysts — they are follicles that stalled before ovulation. And the ovaries are one node in a much larger problem.

We are calling it polyendocrine metabolic ovarian syndrome — PMOS. The rename is not cosmetic. The point is to stop treating one symptom of a whole-body endocrine condition as if the ovary is the cause. Here is what each letter is doing and why it changes how you treat the condition.

The old name framed it as an ovary problem

If your only diagnosis is "polycystic ovary syndrome," the implied treatment is ovary-focused: get your period back, take birth control to suppress androgens, see a gynecologist. That is what most people with PCOS get offered in their twenties, and for many it is the only conversation they ever have with their healthcare system.

The problem is that the cycle is downstream. The reason the cycle is irregular is that insulin and androgens are out of balance upstream. The reason your skin is flaring at the jawline is the same upstream problem. The reason you carry weight around your middle is the same upstream problem. The reason you have a 4–7× higher risk of type 2 diabetes (Rubin et al., J Clin Endocrinol Metab, 2017) and an elevated risk of non-alcoholic fatty liver disease (Wu et al., Endocrine, 2018) is the same upstream problem.

Treating the cycle alone — without touching insulin, inflammation, or the adrenal–ovarian axis — is treating a symptom and ignoring the system.

What "polyendocrine metabolic ovarian" actually means

Polyendocrine says: more than one endocrine organ is involved. The ovaries make excess androgens. The adrenals can make excess androgens too (roughly 20–30% of cases have an adrenal androgen component, measurable as elevated DHEA-S). The thyroid is functionally entangled in a meaningful subset of cases (Singla et al., J Clin Diagn Res, 2015). The hypothalamic–pituitary axis runs the whole show through abnormal pulsatile LH secretion. This is not one gland misbehaving. It is a coordination failure across several.

Metabolic says: insulin resistance is at the core, not at the edge. Roughly 70–80% of people with the condition have measurable insulin resistance, including most lean cases (Stepto et al., Hum Reprod, 2013). High insulin drives the ovaries to make more androgens. High insulin drives the liver to make less sex-hormone-binding globulin, so more of the androgen you do make is free in the bloodstream. High insulin drives belly fat distribution, skin tags, acanthosis nigricans, sugar cravings, and the gradual march toward type 2 diabetes. Almost every symptom most people associate with PCOS — the cycle, the skin, the weight, the hair — has insulin somewhere in its causal chain.

Ovarian stays in the name because the ovary is still the most visible site of the syndrome. Anovulation is what brings most people to a clinician. Polycystic-appearing ovaries on ultrasound are still part of the diagnostic criteria. We are not pretending the ovary is uninvolved. We are saying the ovary is the loudest symptom, not the disease.

Syndrome because it is a constellation, not a single mechanism. Two people can both meet PMOS criteria and have almost nothing in common at the symptom level.

Why this matters when you are actually trying to treat it

The rename matters because it changes the next question.

Under the old name, "what do I do about PCOS?" usually meant "what do I do about my cycle?" The standard answers — birth control, metformin, sometimes spironolactone for skin — all aim at one downstream symptom.

Under the new name, "what do I do about PMOS?" forces a different question: where in the system is my upstream driver? For some people it is primarily insulin and the answer is diet sequencing, strength training, and sometimes inositol or metformin. For others it is primarily adrenal androgens and the answer involves cortisol load, sleep, and an endocrinologist. For others the dominant feature is inflammation in the gut and the answer is fiber, food removal trials, and SIBO workup. For most people it is some combination, in some order, and you find that order by tracking what your body is actually doing.

That is what the AI companion is for. You text it what you ate, what you noticed, what you tried. It looks for the upstream driver in your data instead of guessing from a textbook. The reason we renamed the condition is the same reason we built the product the way we did. The thing is not a cycle problem. It is a system problem. Treat the system.

What is actually changing for you

If a clinician you are talking to still says "PCOS," that is fine. The diagnostic criteria are the same. The Rotterdam framework (Rotterdam ESHRE/ASRM, Hum Reprod, 2004) and the international evidence-based guideline (Teede et al., Hum Reprod, 2023) still apply. PMOS is the same condition under a name that describes it more honestly. You do not need to re-diagnose yourself.

What changes is the conversation. PMOS gives you a framework to ask: what is driving my version of this? That question is harder than "fix my period," and it is the only one that actually gets you to a treatment plan instead of a prescription.

If you are starting from scratch, the first move is not a supplement. It is a thirty-day stretch of logging the inputs your body responds to — meals, sleep, stress, cycle, the symptoms you noticed — and looking at the pattern. Nuravi was built for that part.

The cysts are not cysts. The ovary is not the cause. The name has finally caught up.